Outlook Therapeutics (OTLK) Accumulated Expenses (2015 - 2026)

Outlook Therapeutics (OTLK) has reported Accumulated Expenses for 12 consecutive years, with $9.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 1119.31% year-over-year to $9.0 million; the TTM figure through Mar 2026 stood at $9.0 million (up 1119.31% YoY), while the FY2025 annual figure was $5.3 million, up 64.15% from the prior year.
• Accumulated Expenses grew to $9.0 million in Q1 2026 per OTLK's latest filing, from $1.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $9.0 million in Q1 2026 and bottomed at $741332.0 in Q1 2025.
• Historically, Accumulated Expenses has averaged $2.8 million across 5 years, with a median of $2.5 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 1231173.54% — and 2024, when it plunged 66.03%.
• Outlook Therapeutics' Accumulated Expenses stood at $2.7 million in 2022, then soared by 48.84% to $4.1 million in 2023, then slumped by 66.03% to $1.4 million in 2024, then increased by 11.96% to $1.6 million in 2025, then jumped by 481.48% to $9.0 million in 2026.
• Business Quant data shows OTLK's Accumulated Expenses at $9.0 million in Q1 2026, $1.6 million in Q4 2025, and $5.3 million in Q3 2025.